Navigation Links
MiddleBrook Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:11/13/2008

- -

Common stock, $0.01 par value; 225,000

shares authorized, and 86,420 and

46,749 shares issued and outstanding at

September 30, 2008 and December 31, 2007,

respectively 864 467

Capital in excess of par value 306,743 189,019

Accumulated deficit (225,303) (195,334)

Accumulated other comprehensive income 37 -

Total stockholders' equity (deficit) 82,341 (5,848)

Total liabilities, noncontrolling

interest and stockholders' equity

(deficit) $102,457 $23,666

MiddleBrook Pharmaceuticals, Inc.

Condensed Consolidated Statements of Cash Flows

(Amounts in thousands, except per share amounts)(unaudited)

Nine Months Ended September 30,

2008 2007

Cash flows from operating activities:

Net loss $(29,969) $(33,198)

Adjustments to reconcile net income to

net cash in operating activities:

Loss attributable to noncontrolling

interest (485) -

Depreciation and amortization 5,850 3,447

Change in fair value of warrants 6,714 -

Stock-based compensation 1,256 1,972

Deferred rent and credit on lease

concession (223) (48)

Amortization of premium on marketable

securities (30) (69)

Loss on disposal of fixed as
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. MiddleBrook Pharmaceuticals Raises Up to $10 Million from Deerfield Management
2. MiddleBrook Pharmaceuticals Reports Third Quarter 2007 Results
3. MiddleBrook Pharmaceuticals to Raise $21 Million Through Private Placement of Common Equity
4. MiddleBrook Pharmaceuticals Engages Morgan Stanley in Its Strategic Process
5. MiddleBrook Pharmaceuticals Reports First Quarter 2008 Results
6. MiddleBrook Pharmaceuticals Reports Second Quarter 2008 Results
7. MiddleBrook to Webcast Management Presentation at the 10th Annual Rodman & Renshaw Healthcare Conference
8. MiddleBrook Pharmaceuticals Schedules Conference Call and Webcast for Third Quarter 2008 Financial Results
9. MiddleBrook Pharmaceuticals Retains National Account Firm VCG & Associates
10. MiddleBrook Pharmaceuticals Announces Orange Book Listing of Moxatag(TM) Patents
11. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... France: The Orsiro stent, which is a novel ... demonstrated non-inferiority to the Xience Prime everolimus-eluting stent ... lumen loss at nine months in the results ... today. , The BIOFLOW-II substudy used intravascular ultrasound ... assess neointimal hyperplasia and stent apposition at nine ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The federal ... hip replacement lawsuits in U.S. District Court, ... response to a request from Plaintiffs’ Counsel to conduct ... The May 17th Order grants that request, and ... conducted. (In re: Wright Medical Technology, Inc., Conserve Hip ...
(Date:5/21/2013)... Focus, a non-profit organization striving to improve the living ... Corridor region, is releasing results for its 2013 Creative ... May 23rd at 10:30 a.m. The survey follows ... The survey is a critical component to the organizations’ ... and retain people of diverse backgrounds, cultures and beliefs ...
(Date:5/21/2013)... May 21, 2013 Modern couples ... help of Texas Counseling’s Sexuality and Relationship Workshops, ... the development of healthier habits for their relationship. ... for both couples and individuals at Texas Counseling. ... relationships and learn skills to develop long term ...
(Date:5/21/2013)... (May 21, 2013) Research into genetic features of ... of Colorado School of Medicine may lead to improved ... paper published online by JAMA . , The ... survival in some cases of pulmonary fibrosis, a chronic ... As a result of the study, researchers may want ...
Breaking Medicine News(10 mins):Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 2Health News:Wright Hip Lawsuit News: Bernstein Liebhard LLP Notes Issuance of New Order in Federal Wright Conserve Hip Replacement Litigation 3Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2Health News:Workshops Offered To Identify Underlying Challenges That Put Strain On Relationships 2Health News:Researchers find genetic tie to improved survival time for pulmonary fibrosis 2
... ... Energy power system to supply all the loads in the new tower, including HVAC. ... as a practical matter, because east central Florida is hit frequently by hurricanes and thunderstorms ... ...
... , SAN PEDRO, Calif., Oct. 19 On ... the 11th annual surf cruise to Mexico will host their ... star line up of professional surfers, musicians, artists and movie ... The charity mission includes the W Hollywood Lions Club Global ...
... are already anticipating Halloween "trick or treating," some parents are ... to receive free candy. , Parents of children ... their child is the recipient of food outside the home. ... can stay safe without having to miss out on the ...
... (OTC Bulletin Board: OXBO) shareholders today voted to approve a ... general meeting in which shareholders also voted to approve all ... At the meeting, chairman and CEO Chris Stern also discussed ... Concentrate Gel for the skin care market and discussed an ...
... while blood flow is blocked protects tissue, animal study ... previous research, scientists have shown in animal studies that ... brain damage. , But it,s not a simple matter. ... depends on when 100 percent oxygen is given. ...
... no longer go after users or suppliers in states that ... News) -- The Obama administration has decided it will no ... the laws of states that allow use of the drug ... be sent in a Justice Department memo to federal prosecutors ...
Cached Medicine News:Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 2Health News:Florida's Halifax Health Relies on Standby Power System from MTU Onsite Energy for New 10-Story Emergency Facility 3Health News:SURF CRUISE CUP 2009 2Health News:Halloween Doesn't Have to Be Scary for Kids With Food Allergies 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 2Health News:Oxygen Biotherapeutics, Inc. Shareholders Approve Reverse Stock Split 3Health News:Timing of Oxygen After a Stroke May Matter 2Health News:U.S. Relaxes Opposition to Medical Marijuana 2Health News:U.S. Relaxes Opposition to Medical Marijuana 3
(Date:5/21/2013)... YORK , May 21, 2013 /PRNewswire/ ... research report is available in its catalogue: ... Markets and Technologies for Optical Coherence Tomography ...   STUDY OBJECTIVES ... this study is to offer synopsis of ...
(Date:5/21/2013)... and TARRYTOWN, N.Y. , May ... SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced ... published online the positive Phase 2a study results of ... is an investigational monoclonal antibody targeting the alpha subunit ... signaling of both IL-4 and IL-13, drivers of Th2 ...
(Date:5/21/2013)... MOUNTAIN VIEW, Calif. , May 21, 2013 /PRNewswire/ ... Brazil , Russia , ... (BRIC) are realizing there are no shortcuts.  This ... especially in the United States.  Companies must change the ... establishing value, customizing to local needs, and building regional ...
Breaking Medicine Technology:Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 2Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 3Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 4Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 5Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 6Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine 7Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 2Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 3Frost & Sullivan: BRIC is Not Delivering Promises of High Growth in Healthcare Markets 4
... VIEW, Calif., Nov. 8, 2011 ChemoCentryx, Inc., today ... CCX354 at the Annual Meeting of the American College ... that specifically targets and inhibits the chemokine receptor known ... progression of rheumatoid arthritis (RA).  Results showed that CCX354 ...
... 8, 2011 Covance Inc. (NYSE: CVD ) ... Healthcare Conference on Thursday, November 10, 2011 at 3:00 p.m. ... at www.covance.com .  In order to register and download ... Covance, with headquarters in Princeton, New Jersey, is one ...
Cached Medicine Technology:ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 2ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 3ChemoCentryx Reports Clinical Efficacy for CCX354, a Novel CCR1 Inhibitor in a Phase II Study in Patients with Rheumatoid Arthritis 4Covance to Present at Credit Suisse 2011 Healthcare Conference 2
Inquire...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: